
We report results of a phase I trial and zzso study of zzso zzso in children and adolescents with zzso solid zzso zzso is a novel zzso that zzso multiple zzso necessary for the zzso of zzso and zzso zzso The purpose of this study was to determine the zzso dose zzso zzso zzso zzso and zzso properties of zzso in zzso 

zzso was administered as a 10-minute intravenous infusion every 21 zzso Patients received vitamin B12 and zzso acid supplementation as well as zzso zzso zzso of three to six children were enrolled at dose levels of 400, zzso zzso zzso zzso zzso zzso and 2,480 zzso zzso studies were performed during the first course of zzso 

zzso patients zzso zzso with a median age of 12 years were zzso zzso occurred in one of six patients at zzso zzso and two of four patients at 2,480 zzso The zzso was zzso zzso The primary zzso were zzso and zzso No objective zzso responses were zzso Mean plasma zzso zzso and zzso volume of distribution values were zzso zzso zzso hours, and zzso zzso zzso 

zzso is zzso in children with zzso solid tumors at doses similar to the zzso in zzso The recommended dose for phase II studies is zzso zzso administered every 21 days with zzso zzso acid, and vitamin B12 zzso 

